DJ‐1 deficiency triggers microglia sensitivity to dopamine toward a pro‐inflammatory phenotype that is attenuated by rasagiline

DJ‐1 is an oxidative stress sensor that localizes to the mitochondria when the cell is exposed to oxidative stress. DJ‐1 mutations that result in gene deficiency are linked to increased risk of Parkinson's disease (PD). Activation of microglial stress conditions that are linked to PD may result in neuronal death. We postulated that DJ‐1 deficiency may increase microglial neurotoxicity. We found that down‐regulation of DJ‐1 in microglia using an shRNA approach increased cell sensitivity to dopamine as measured by secreted pro‐inflammatory cytokines such as IL‐1β and IL‐6. Furthermore, we discovered that DJ‐1‐deficient microglia had increased monoamine oxidase activity that resulted in elevation of intracellular reactive oxygen species and nitric oxide leading to increased dopaminergic neurotoxicity. Rasagaline, a monoamine oxidase inhibitor approved for treatment of PD, reduced the microglial pro‐inflammatory phenotype and significantly reduced neurotoxicity. Moreover, we discovered that DJ‐1‐deficient microglia have reduced expression of triggering receptor expressed on myeloid cells 2 (TREM2), previously suggested as a risk factor for pro‐inflammation in neurodegenerative diseases. Further studies of DJ‐1‐mediated cellular pathways in microglia may contribute useful insights into the development of PD providing future avenues for therapeutic intervention.

[1]  R. Leak,et al.  Neurotransmitter receptors on microglia , 2016, Stroke and Vascular Neurology.

[2]  M. Goldberg,et al.  Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1−/− mice , 2013, Journal of Neuroinflammation.

[3]  E. Melamed,et al.  Knocking Out DJ-1 Attenuates Astrocytes Neuroprotection Against 6-Hydroxydopamine Toxicity , 2013, Journal of Molecular Neuroscience.

[4]  E. Melamed,et al.  DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[5]  S. Tabrizi,et al.  Mutant huntingtin impairs immune cell migration in Huntington disease. , 2012, The Journal of clinical investigation.

[6]  A. Canellada,et al.  Dopamine Agonists Upregulate IL-6 and IL-8 Production in Human Keratinocytes , 2012, Neuroimmunomodulation.

[7]  S. Eaton,et al.  Microglial neurotransmitter receptors trigger superoxide production in microglia; consequences for microglial–neuronal interactions , 2012, Journal of neurochemistry.

[8]  L. Peterson,et al.  Oxidative Stress and Microglial Cells in Parkinson's Disease , 2012, Mediators of inflammation.

[9]  R. Ransohoff,et al.  The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood , 2012, The Journal of Immunology.

[10]  A. Tolkovsky,et al.  Inhibition of Microglial Phagocytosis Is Sufficient To Prevent Inflammatory Neuronal Death , 2011, The Journal of Immunology.

[11]  D. Farfara,et al.  γ‐Secretase component presenilin is important for microglia β‐amyloid clearance , 2011, Annals of neurology.

[12]  F. Jessen,et al.  The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease , 2010, Molecular medicine.

[13]  K. Takahashi-Niki,et al.  DJ-1 binds to mitochondrial complex I and maintains its activity. , 2009, Biochemical and biophysical research communications.

[14]  D. Cleveland,et al.  Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond , 2009, The Journal of cell biology.

[15]  J. Rogers,et al.  Microglial responses to dopamine in a cell culture model of Parkinson's disease , 2009, Neurobiology of Aging.

[16]  B. Thomas Parkinson's disease: from molecular pathways in disease to therapeutic approaches. , 2009, Antioxidants & redox signaling.

[17]  W. Wurst,et al.  Regulation of astrocyte inflammatory responses by the Parkinson's disease‐associated gene DJ–1 , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A. Suzumura [Neurotoxicity by microglia: the mechanisms and potential therapeutic strategy]. , 2009, Fukuoka igaku zasshi = Hukuoka acta medica.

[19]  W. Schulz-Schaeffer,et al.  Screening of innate immune receptors in neurodegenerative diseases: A similar pattern , 2009, Neurobiology of Aging.

[20]  M. Giorgio,et al.  Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase , 2009, Basic Research in Cardiology.

[21]  B. Liu,et al.  The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery , 2008, Fundamental & clinical pharmacology.

[22]  Daniel Offen,et al.  Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. , 2008, Neurotoxicology.

[23]  H. Weiner,et al.  A nasal proteosome adjuvant activates microglia and prevents amyloid deposition , 2008, Annals of neurology.

[24]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[25]  K. Suk,et al.  Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. , 2008, International immunopharmacology.

[26]  J. Andersen,et al.  MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology , 2008, PloS one.

[27]  H. Kettenmann,et al.  Neurotransmitter receptors on microglia , 2007, Trends in Neurosciences.

[28]  H. Neumann,et al.  Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis , 2007, Journal of Neuroimmunology.

[29]  A. Bruce-Keller,et al.  SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells , 2007, Journal of Neuroimmunology.

[30]  R. Gold,et al.  Phagocytosis of apoptotic inflammatory cells downregulates microglial chemoattractive function and migration of encephalitogenic T cells , 2006, Journal of neuroscience research.

[31]  N. Wood,et al.  Understanding the molecular causes of Parkinson's disease. , 2006, Trends in molecular medicine.

[32]  L. Piccio,et al.  Cutting Edge: TREM-2 Attenuates Macrophage Activation1 , 2006, The Journal of Immunology.

[33]  G. Weissmann,et al.  Science fraud: from patchwork mouse to patchwork data , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  P. Carvey,et al.  Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis , 2006, Cell transplantation.

[35]  K. Tracey,et al.  Immunologic Role of the Cholinergic Anti‐Inflammatory Pathway and the Nicotinic Acetylcholine α7 Receptor , 2005, Annals of the New York Academy of Sciences.

[36]  Reidun Torp,et al.  Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.

[37]  Tiffany Mathews,et al.  Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice* , 2005, Journal of Biological Chemistry.

[38]  H. Kettenmann,et al.  Dopamine and noradrenaline control distinct functions in rodent microglial cells , 2005, Molecular and Cellular Neuroscience.

[39]  V. Bader,et al.  Expression of DJ-1 in the adult mouse CNS , 2005, Brain Research.

[40]  David S. Park,et al.  Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  David W. Miller,et al.  Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. , 2005, Brain research. Molecular brain research.

[42]  J. Feldon,et al.  Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease , 2005, Neuroscience Letters.

[43]  P. Calabresi,et al.  Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1 , 2005, Neuron.

[44]  Jiang Li,et al.  Rotenone‐induced caspase 9/3‐independent and ‐dependent cell death in undifferentiated and differentiated human neural stem cells , 2005, Journal of neurochemistry.

[45]  P. Mcgeer,et al.  Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.

[46]  A. Schwab,et al.  Functional importance of Ca2+‐activated K+ channels for lysophosphatidic acid‐induced microglial migration , 2004, The European journal of neuroscience.

[47]  T. Niki,et al.  DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.

[48]  H. Ariga,et al.  Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. , 2003, Biochemical and biophysical research communications.

[49]  Richard Mayeux,et al.  Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.

[50]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[51]  N. Quinn,et al.  The role of pathogenic DJ‐1 mutations in Parkinson's disease , 2003, Annals of neurology.

[52]  T. Sherer,et al.  The rotenone model of Parkinson's disease: genes, environment and mitochondria. , 2003, Parkinsonism & related disorders.

[53]  Todd B. Sherer,et al.  Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.

[54]  D. Calne,et al.  Familial and sporadic Parkinson's disease usually display the same clinical features. , 2003, Parkinsonism & related disorders.

[55]  T. Niki,et al.  DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. , 2003, Molecular cancer research : MCR.

[56]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[57]  J. Sutcliffe,et al.  Heterogeneous expression of the triggering receptor expressed on myeloid cells‐2 on adult murine microglia , 2002, Journal of neurochemistry.

[58]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[59]  R. Moots,et al.  Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study , 2002, Journal of Neuroimmunology.

[60]  D. Miller,et al.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  J. Li,et al.  Free radicals in Parkinson's disease , 2002, Journal of Neurology.

[62]  Andreas Hartmann,et al.  Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP , 2002, Experimental Neurology.

[63]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[64]  E. Junn,et al.  Apoptotic signaling in dopamine‐induced cell death: the role of oxidative stress, p38 mitogen‐activated protein kinase, cytochrome c and caspases , 2001, Journal of neurochemistry.

[65]  W Tatton,et al.  The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo , 2001, Annals of the New York Academy of Sciences.

[66]  M. Naoi,et al.  Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022 , 2001, Annals of the New York Academy of Sciences.

[67]  M. Youdim,et al.  Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B , 2001, British journal of pharmacology.

[68]  Nir Giladi,et al.  Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa , 2000, Clinical neuropharmacology.

[69]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[70]  J. Cano,et al.  The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System , 2000, Neurobiology of Disease.

[71]  E. Hirsch Glial cells and Parkinson’s disease , 2000, Journal of Neurology.

[72]  M. Levite Nerve‐Driven Immunity: The Direct Effects of Neurotransmitters on T‐Cell Function , 2000, Annals of the New York Academy of Sciences.

[73]  J. Joseph,et al.  Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. , 1999, Free radical biology & medicine.

[74]  T. Joh,et al.  Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos , 1999, The Journal of Neuroscience.

[75]  S. Fahn,et al.  Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop , 1998, Movement disorders : official journal of the Movement Disorder Society.

[76]  K. Onozaki,et al.  Serotonin Derivative, N-(p-Coumaroyl) Serotonin, Inhibits the Production of TNF-α, IL-1α, IL-1β, and IL-6 by Endotoxin-Stimulated Human Blood Monocytes , 1998 .

[77]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[78]  J. Bernhagen,et al.  Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features , 1998, Journal of Molecular Medicine.

[79]  H. Nawashiro,et al.  TNF-α Pretreatment Induces Protective Effects against Focal Cerebral Ischemia in Mice , 1997 .

[80]  T. Taira,et al.  DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. , 1997, Biochemical and biophysical research communications.

[81]  J. Glowinski,et al.  Astrocytes protect neurons from hydrogen peroxide toxicity , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[83]  P. Lapchak,et al.  Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: Selective effects on specific interleukins and interleukin receptors , 1994, Neuroscience.

[84]  H. Misra,et al.  Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1993, The Journal of biological chemistry.

[85]  C. Galanos,et al.  Mechanisms of endotoxin shock and endotoxin hypersensitivity. , 1993, Immunobiology.

[86]  H. Fahmi,et al.  Selective refractoriness of macrophages to endotoxin‐induced production of tumor necrosis factor, elicited by an autocrine mechanism , 1993, Journal of leukocyte biology.

[87]  T. Molitor,et al.  Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. , 1992, Journal of immunology.

[88]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[89]  S. Yamazaki,et al.  Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. , 1986, Japanese Journal of Medical Science & Biology.

[90]  V. Luine,et al.  Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain , 1975, Brain Research.

[91]  K. Fountas,et al.  Genetic basis of Parkinson disease. , 2010, Neurosurgical focus.

[92]  J. Rogers,et al.  Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.

[93]  R. Stein,et al.  Characterization of LPS and interferon-γ triggered activation-induced cell death in N9 and primary microglial cells: induction of the mitochondrial gateway by nitric oxide , 2007, Cell Death and Differentiation.

[94]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[95]  E. Hirsch,et al.  Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. , 2002, Experimental neurology.

[96]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[97]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[98]  K. Onozaki,et al.  Serotonin derivative, N-(p-coumaroyl) serotonin, inhibits the production of TNF-alpha, IL-1alpha, IL-1beta, and IL-6 by endotoxin-stimulated human blood monocytes. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[99]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[100]  H. Nawashiro,et al.  TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[101]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[102]  G. Cohen,et al.  Monoamine oxidase and oxidative stress at dopaminergic synapses. , 1990, Journal of neural transmission. Supplementum.

[103]  I. Fabian,et al.  Monoamine oxidase activity of macrophages at rest and during phagocytosis. , 1978, Biochemical pharmacology.

[104]  Mancheva-Ganeva Velina,et al.  Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .

[105]  K. Lambertsen,et al.  Journal of Neuroinflammation Interleukin-1beta and Tumor Necrosis Factor-alpha Are Expressed by Different Subsets of Microglia and Macrophages after Ischemic Stroke in Mice , 2022 .